Quantification of genotype 4 hepatitis C virus RNA by the COBAS AmpliPrep/COBAS TaqMan hepatitis C virus test
Jeffrey J. Germer, Carl E. Bommersbach, Dana M. Schmidt, Jordan L. Bendel, Joseph D. C. Yao – 29 October 2009
What does the long‐term liver allograft look like for the pediatric recipient?
Stefan Hübscher – 29 October 2009 – Key Points
Obesity, hyperlipidemia, and metabolic syndrome
Michael Charlton – 29 October 2009 – Key Points
Hepatic congestion plays a role in liver stiffness
Nora Frulio, Hervé Laumonier, Charles Balabaud, Hervé Trillaud, Paulette Bioulac‐Sage – 29 October 2009
De novo malignancies following liver transplantation: Impact and recommendations
J. Ignacio Herrero – 29 October 2009 – Key Points
Long‐term medical comorbidities and their management: Hypertension/cardiovascular disease
Olaf Guckelberger – 29 October 2009 – Key Points
Health‐related quality of life after liver transplantation for adult recipients
Hillary Bownik, Sammy Saab – 29 October 2009 – Key Points
Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation
Jean‐Charles Duclos‐Vallee, Mylène Sebagh – 29 October 2009 – Key Points
Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A
Sandra Ciesek, Eike Steinmann, Heiner Wedemeyer, Michael P. Manns, Johann Neyts, Norbert Tautz, Vanesa Madan, Ralf Bartenschlager, Thomas von Hahn, Thomas Pietschmann – 29 October 2009 – Numerous anti‐hepatitis C virus (HCV) drugs targeting either the viral nonstructural 3 (NS3) protease or NS5B polymerase are currently in clinical testing. However, rapid resistance development is a major problem and optimal therapy will clearly require a combination of multiple mechanisms of action.
Sirtuins and the hepatic regulation of energy homeostasis
Puneet Puri, Arun J. Sanyal – 29 October 2009